The M S T report was just a brief update. Some points;x NEU has...

The M S T report was just a brief update. Some points;
x NEU has created a "production line" offering an extensive target list and an expedited development pathway
x Existing data from 2591 should support IND applications and Phase 2 development of other target indications such as PW
x DCF valuation of $463M (previously $433M).
x Board and Management are well credentialled with in depth expertise in drug development and commercialisation.
So, their model essentially values PW, on a risk weighted basis, at $30M. My model values it on a risk weighted basis and using 15% WACC at $180M....wind the clock forward 2 years, and if neuren still exists as a listed ASX entity, then let's see who is wrong. I can hear the murmurs already......they're the experts Phlipper, you're just a mug retail investor....anyway....